It's sunny and he's been approved for the first copy of the Nofowe film

On June 9, China Biopharmaceuticals announced that the group developed the treatment of AIDS drug Entretabinofovir tablets (commodity name: Keaico) has been issued by the State Drug Administration drug registration approval, for the generic drug of the first domestic approval, and as the same through the consistent evaluation. Entourtabinofove tablets are used to treat HIV-1 infections in adults and children over 12 years of age (inclusive), formerly of Gilead. In 2019, Entourin Pentino's global sales will be $2.8 billion, according to Minernet.Data show that entourtabinofovir tablets contain two active ingredients - entourtabin and fumarate nofovir difficide, both highly effective antiretroviral drugs. Entourtabinofove tablets are single tablets, with simplified treatment, remarkable efficacy, high patient compliance, low drug resistance and so on, has been included in the 2017 edition of the National Health Insurance Directory.
In recent years, Gilead's Sales at Enquentino Nofowe have declined year-on-year, from $3,566 million in 2016 to $2,813 million in 2019, according to Minernet. In China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal Enqutai Bin tinofowe 2019 sales of 46.63 million yuan, an increase of 86.59 percent year-on-year.Up to now, the product also has Qilu Pharmaceuticals, Sichuan Haisco, Anhui Baker Biopharmaceutical imitation 4 categories of listing applications are being reviewed and approved, once approved will be treated as passing a consistent evaluation.China Biopharmaceutical said that there is currently no Entourturtent Nofowe tablet generic drug market, the original research imported products are expensive, greatly increase the cost of patients, it is difficult to have universal. The approval of this heavy-weight product will expand the clinical drug options for the treatment of HIV-1, reduce the burden of drug use for patients, and have broad market prospects. (Minenet)